Table 1.
Summary of LTD-LTP studies.
Condition (N) | LFS (%) | HFS (%) |
---|---|---|
Control (6) | 65.9 ± 5.9 | 67.3 ± 5.7 |
50 μmol/L D-APV during LFS (6) | 107.5 ± 3.2 | 143.9 ± 9.2 |
5 μmol/L D-APV during LFS (5) | 79.9 ± 4.5 | 102.1 ± 24.8 |
5 μmol/L D-APV continuously (5) | 73.8 ± 2.9 | 92.3 ± 5.3 |
1 μmol/L PTX continuously (5) | 102.4 ± 2.8 | 166.4 ± 18.9 |
1 μmol/L Finasteride continuously (5) | 104.1 ± 12.0 | 134.2 ± 14.2 |
1 μmol/L Finasteride during LFS (5) | 97.8 ± 2.9 | 91.6 ± 7.3 |
1 μmol/L Finasteride after LFS (5) | 56.6 ± 4.8 | 101.5 ± 13.4 |